BR9909925A - Compostos, composições farmacêuticas, e, processos para a fabricação de um composto, e de tratamento de um mamìfero sofrendo de doenças resultantes da autoimunidade e inflamação patológica - Google Patents
Compostos, composições farmacêuticas, e, processos para a fabricação de um composto, e de tratamento de um mamìfero sofrendo de doenças resultantes da autoimunidade e inflamação patológicaInfo
- Publication number
- BR9909925A BR9909925A BR9909925-0A BR9909925A BR9909925A BR 9909925 A BR9909925 A BR 9909925A BR 9909925 A BR9909925 A BR 9909925A BR 9909925 A BR9909925 A BR 9909925A
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- compound
- compounds
- autoimmunity
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTOS, COMPOSIçõES FARMACêUTICAS, E, PROCESSOS PARA A FABRICAçãO DE UM COMPOSTO, E DE TRATAMENTO DE UM MAMìFERO SOFRENDO DE DOENçAS RESULTANTES DA AUTOIMUNIDADE E INFLAMAçãO PATOLóGICA" A invenção diz respeito aos compostos da fórmula geral (I) em que R é selecionado do etila, n-propila, isopropila, n-butila, isobutila, secbutila e alila; R~ 4~ é selecionado de hidrogênio e cátions inorgânicos e orgânicos farmaceuticamente aceitáveis; R~ 5~ é selecionado de metila, etila, n-propila, isopropila, metóxi, etóxi, cloro, bromo, CF~ 3~ e OCH~ x~F~ y~; em que x = 0 a 2, y = 1 a 3 com a condição de que x + y = 3; R~ 6~ 'e hidrogênio; ou R~ 5~ e R~ 6~ tomados juntos são metilenodióxi; e qualquer tautómero destes. A invenção também diz respeito a composições farmacêuticas que contêm um composto da fórmula geral (I) junto com um veículo farmaceuticamente aceitável. Também estão incluídos processos para a preparação dos compostos da fórmula (I), bem como processos para tratar de mamíferos que sofram de doenças resultantes da auto-imunidade e de inflamações patológicas mediante administração de um composto tendo a formula (I) a dito mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801474A SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Quinoline Derivatives |
| PCT/SE1999/000676 WO1999055678A1 (en) | 1998-04-27 | 1999-04-26 | Quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9909925A true BR9909925A (pt) | 2001-01-09 |
| BR9909925B1 BR9909925B1 (pt) | 2010-09-21 |
Family
ID=20411103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9909925-0A BR9909925B1 (pt) | 1998-04-27 | 1999-04-26 | derivados de quinolina, composições farmacêuticas, e, processo para a fabricação de derivados de quinolina. |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1073639B1 (pt) |
| JP (1) | JP4045069B2 (pt) |
| KR (1) | KR100571534B1 (pt) |
| CN (1) | CN1113057C (pt) |
| AP (1) | AP1293A (pt) |
| AT (1) | ATE228505T1 (pt) |
| AU (1) | AU747550B2 (pt) |
| BR (1) | BR9909925B1 (pt) |
| CA (1) | CA2329788C (pt) |
| CZ (1) | CZ297439B6 (pt) |
| DE (1) | DE69904162T2 (pt) |
| DK (1) | DK1073639T3 (pt) |
| EE (1) | EE04275B1 (pt) |
| ES (1) | ES2188242T3 (pt) |
| HK (1) | HK1036618A1 (pt) |
| HR (1) | HRP20000726B1 (pt) |
| HU (1) | HU227709B1 (pt) |
| ID (1) | ID26277A (pt) |
| IL (2) | IL138160A0 (pt) |
| IS (1) | IS2082B (pt) |
| ME (1) | ME00870B (pt) |
| NO (1) | NO315606B1 (pt) |
| NZ (1) | NZ506641A (pt) |
| OA (1) | OA11547A (pt) |
| PL (1) | PL190441B1 (pt) |
| PT (1) | PT1073639E (pt) |
| RS (1) | RS50029B (pt) |
| RU (1) | RU2197481C2 (pt) |
| SE (1) | SE9801474D0 (pt) |
| TR (1) | TR200003061T2 (pt) |
| UA (1) | UA60354C2 (pt) |
| WO (1) | WO1999055678A1 (pt) |
| ZA (1) | ZA200004601B (pt) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| KR100908655B1 (ko) | 2002-11-27 | 2009-07-21 | 엘지디스플레이 주식회사 | 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치 |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| WO2006067114A1 (en) | 2004-12-21 | 2006-06-29 | Laboratoires Serono S.A. | Sulfonyl amino cyclic derivatives and use thereof |
| KR20070105326A (ko) | 2005-01-31 | 2007-10-30 | 라보라뚜와르 세로노 에스. 에이. | Ｎ-하이드록시아미드 유도체 및 그것의 용도 |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| WO2007025991A2 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
| CN107176923A (zh) * | 2005-10-19 | 2017-09-19 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
| UA96449C2 (en) * | 2006-06-12 | 2011-11-10 | Тева Фармасьютикл Индастриз, Лтд. | Stable laquinimod preparations |
| PL2234485T3 (pl) | 2007-12-20 | 2014-06-30 | Teva Pharma | Stabilne preparaty lakwinimodu |
| MX2011002033A (es) | 2008-09-03 | 2011-05-02 | Teva Pharma | 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune. |
| CA2769623A1 (en) * | 2009-07-30 | 2011-02-03 | Teva Pharmaceutical Industries Ltd. | Treatment of crohn's disease with laquinimod |
| ES2586843T3 (es) * | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
| CN105796556A (zh) | 2010-03-03 | 2016-07-27 | 泰华制药工业有限公司 | 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎 |
| PE20130613A1 (es) | 2010-03-03 | 2013-06-23 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod |
| EP2542080B1 (en) * | 2010-03-03 | 2016-08-31 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus arthritis using laquinimod |
| WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
| JP5881691B2 (ja) * | 2010-07-09 | 2016-03-09 | アクティブ バイオテック エイビー | キノリン−３−カルボキサミドの製造方法 |
| AU2011274502A1 (en) * | 2010-07-09 | 2013-02-28 | Teva Pharmaceutical Industries Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| CA2804986A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| EP2444086A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US8975279B2 (en) * | 2012-11-07 | 2015-03-10 | Teva Pharmaceutical Industries, Ltd. | Amine salts of laquinimod |
| RU2545056C2 (ru) * | 2012-12-10 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) | Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты |
| CA2900503A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| EP2970129A2 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
| KR102533033B1 (ko) | 2014-09-23 | 2023-05-15 | 액티브 바이오테크 에이비 | 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드 |
| CN107072989B (zh) | 2014-11-19 | 2020-07-03 | 活跃生物技术有限公司 | 用于治疗白血病的喹啉甲酰胺 |
| CA3157394A1 (en) | 2019-12-19 | 2021-06-24 | Helena ERIKSSON | Compounds for treatment of eye diseases associated with excessive vascularisation |
| EP4114368A1 (en) | 2020-03-03 | 2023-01-11 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| CN115836056A (zh) * | 2020-05-21 | 2023-03-21 | Stemsynergy疗法有限责任公司 | Notch抑制剂及其用途 |
| MX2023000903A (es) | 2020-07-23 | 2023-04-20 | Univ Erasmus Med Ct Rotterdam | Proteinas s100 como nuevos objetivos terapeuticos en neoplasias mieloproliferativas. |
| EP4277628A1 (en) | 2021-01-18 | 2023-11-22 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| CA3218977A1 (en) | 2021-05-25 | 2022-12-01 | Hans Wannman | A plurality of tasquinimod particles and use thereof |
| EP4363404A1 (en) | 2021-07-02 | 2024-05-08 | Active Biotech AB | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-04-27 SE SE9801474A patent/SE9801474D0/xx unknown
-
1999
- 1999-04-26 ME MEP-2000-612A patent/ME00870B/me unknown
- 1999-04-26 OA OA1200000301A patent/OA11547A/en unknown
- 1999-04-26 CA CA002329788A patent/CA2329788C/en not_active Expired - Fee Related
- 1999-04-26 CN CN99805581A patent/CN1113057C/zh not_active Expired - Fee Related
- 1999-04-26 TR TR2000/03061T patent/TR200003061T2/xx unknown
- 1999-04-26 PT PT99947036T patent/PT1073639E/pt unknown
- 1999-04-26 AU AU43013/99A patent/AU747550B2/en not_active Ceased
- 1999-04-26 WO PCT/SE1999/000676 patent/WO1999055678A1/en active IP Right Grant
- 1999-04-26 NZ NZ506641A patent/NZ506641A/en not_active IP Right Cessation
- 1999-04-26 RS YUP-612/00A patent/RS50029B/sr unknown
- 1999-04-26 DK DK99947036T patent/DK1073639T3/da active
- 1999-04-26 UA UA2000085078A patent/UA60354C2/uk unknown
- 1999-04-26 AT AT99947036T patent/ATE228505T1/de active
- 1999-04-26 AP APAP/P/2000/001933A patent/AP1293A/en active
- 1999-04-26 JP JP2000545838A patent/JP4045069B2/ja not_active Expired - Lifetime
- 1999-04-26 EP EP99947036A patent/EP1073639B1/en not_active Expired - Lifetime
- 1999-04-26 ID IDW20002183A patent/ID26277A/id unknown
- 1999-04-26 IL IL13816099A patent/IL138160A0/xx active IP Right Grant
- 1999-04-26 KR KR1020007011944A patent/KR100571534B1/ko not_active IP Right Cessation
- 1999-04-26 ES ES99947036T patent/ES2188242T3/es not_active Expired - Lifetime
- 1999-04-26 BR BRPI9909925-0A patent/BR9909925B1/pt not_active IP Right Cessation
- 1999-04-26 DE DE69904162T patent/DE69904162T2/de not_active Expired - Lifetime
- 1999-04-26 PL PL99343420A patent/PL190441B1/pl unknown
- 1999-04-26 HU HU0102084A patent/HU227709B1/hu not_active IP Right Cessation
- 1999-04-26 EE EEP200000613A patent/EE04275B1/xx unknown
- 1999-04-26 CZ CZ20003849A patent/CZ297439B6/cs not_active IP Right Cessation
- 1999-04-26 RU RU2000129672/04A patent/RU2197481C2/ru not_active IP Right Cessation
-
2000
- 2000-08-30 IL IL138160A patent/IL138160A/en not_active IP Right Cessation
- 2000-08-31 IS IS5615A patent/IS2082B/is unknown
- 2000-09-01 ZA ZA200004601A patent/ZA200004601B/en unknown
- 2000-10-19 NO NO20005254A patent/NO315606B1/no not_active IP Right Cessation
- 2000-10-26 HR HR20000726A patent/HRP20000726B1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 HK HK01105489A patent/HK1036618A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9909925A (pt) | Compostos, composições farmacêuticas, e, processos para a fabricação de um composto, e de tratamento de um mamìfero sofrendo de doenças resultantes da autoimunidade e inflamação patológica | |
| BR9912109A (pt) | Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratar um mamìfero sofrendo de inflamação patológica e autoimunidade | |
| BR9912104A (pt) | Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratamento de um mamìfero, que sofra de inflamação patológica e autoimunidade | |
| TR200000837A2 (tr) | Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler. | |
| EA200001224A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
| EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| AR070473A2 (es) | Compuestos inhibidores de la renina, un procedimiento de preparacion del compuesto, una composicion farmaceutica, uso del compuesto para preparar un medicamento y compuesto intermediario | |
| EA199700117A1 (ru) | Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов | |
| ATE306261T1 (de) | Antithrombosemittel | |
| BR0313743A (pt) | Benzimidazol quinolinonas e usos destas | |
| KR860004882A (ko) | 항 알레르기제로서 유용한 신규의 산성 인돌화합물 및 그 제조방법 | |
| IL154537A0 (en) | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith | |
| ES2168581T3 (es) | Derivados de indazol sustituidos. | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| BR9916422A (pt) | Saponinas antiprotozoárias | |
| ATE21246T1 (de) | Substituierte imidazol-derivate mit pharmakologischer wirkung sowie ihre herstellung und verwendung. | |
| EA200000996A1 (ru) | Конденсированные с арилом азаполициклические соединения | |
| SE8500996D0 (sv) | Method of treatment | |
| DE60107832D1 (en) | Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe | |
| BR0013306A (pt) | Processos úteis na sìntese de compostos antipicornavirais | |
| ES2176758T3 (es) | Procedimiento para la preparacion de 4-ciona-1,2,3-triazxoles. | |
| ES2165067T3 (es) | Nuevos derivados aromaticos sustituidos con una ribosa, su procedimiento de preparacion y su aplicacion como medicamentos. | |
| IT1205640B (it) | Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/09/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |